Georgiamune Inc
Clinical trials sponsored by Georgiamune Inc, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a Dual-Action antibody outsmart resistant tumors? Results expected Sep 2026 (estimated)
- New pill aims to boost immune attack on Hard-to-Treat cancers Results expected Dec 2026 (estimated)
-
Can a Dual-Action antibody outsmart resistant tumors?
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to fin…
Phase 1/2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New pill aims to boost immune attack on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…
Phase 1/2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC